Get Live Data

Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. Block Listing Application

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1950.00    -7.50 (-0.38%)
Bid:
1954.50
Ask:
1955.00
Spread: 0.50 (0.026%)
Market Cap: £78.13b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block Listing Application

11 Dec 2025 09:00

RNS Number : 0709L
GSK PLC
11 December 2025
 

 

Issued: 11 December 2025, London UK

 

Block Listing Application

 

 

Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 250,000 Ordinary Shares of 31¼p each ('Shares') to be admitted to the Official List.

 

The Shares are being reserved under a block listing and will be issued under the GlaxoSmithKline plc Share Save Plan 2022.

 

When issued, the Shares will rank pari passu with the existing Ordinary Shares of 31¼p each.

 

Admission is expected to be effective on 12 December 2025.

 

 

 

 

V A Whyte

Company Secretary

 

11 December 2025

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSPKKBDABDDFBD
456789101112
Date   Source Headline
23rd Jun 20258:30 amRNSReplacement RNS: Linerixibat file accepted by EMA
23rd Jun 20258:18 amRNSGSK Submits Arexvy for adults 18+ with EMA
23rd Jun 20257:00 amRNSTransaction in Own Shares
20th Jun 20257:00 amRNSArexvy filed in Japan for 18-49 at increased risk
20th Jun 20257:00 amRNSTransaction in Own Shares
19th Jun 20257:00 amRNSTransaction in Own Shares
18th Jun 20257:00 amRNSTransaction in Own Shares
17th Jun 20257:00 amRNSTransaction in Own Shares
16th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20253:30 pmRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20257:00 amRNSGSK submits Arexvy for adults 18+ with EMA
12th Jun 202511:00 amPRNDirector/PDMR Shareholding
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20253:30 pmRNSDirector/PDMR Shareholding
11th Jun 20257:00 amRNSTransaction in Own Shares
10th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSGSK - second tranche of share buyback programme
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20253:30 pmRNSDirector/PDMR Shareholding
2nd Jun 20253:00 pmRNSTotal Voting Rights
2nd Jun 20257:00 amRNSLinerixibat file accepted for review by US FDA
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 202512:00 pmRNSGSK stops Phase 3 trial on cUTIs for efficacy
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 202512:16 pmRNSpositive CHMP opinion on Blenrep in EU
23rd May 20257:00 amRNSFDA approves Nucala COPD indication
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20253:30 pmRNSDirector/PDMR Shareholding
20th May 20257:00 amRNSTransaction in Own Shares
19th May 20257:00 amRNSBlenrep for 2L+ multiple myeloma approved in Japan
19th May 20257:00 amRNSTransaction in Own Shares
16th May 20257:00 amRNSTransaction in Own Shares
15th May 20257:00 amRNSTransaction in Own Shares
14th May 20257:00 amRNSGSK to acquire efimosfermin
14th May 20257:00 amRNSTransaction in Own Shares
13th May 20253:30 pmRNSDirector/PDMR Shareholding
13th May 202512:56 pmRNSUpdate on belrestotug development programme
13th May 20257:00 amRNSTransaction in Own Shares
12th May 20253:31 pmRNSBlock listing Interim Review
12th May 20257:00 amRNSTransaction in Own Shares
456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
IPO
Ip Group
LSE
-0.61%
ECM
ECM.L
LSE
0.00%
DRTY
DRTY.L
LSE
0.00%
DOR
Doriemus
LSE
0.00%
FEN
Frenkel Topping
LSE
0.00%
Trending
RRR
Red Rock Resources
LSE
4.35%
CBG
Close Bros
LSE
-0.27%
GGP
Greatland Resources
LSE
-6.61%
MCG
Mobico Group
LSE
3.51%
80M
80 Mile
LSE
-1.54%